Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Tayor & Francis Country of Publication: England NLM ID: 9606000 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1366-5804 (Electronic) Linking ISSN: 1354750X NLM ISO Abbreviation: Biomarkers Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Abingdon, Oxford : Tayor & Francis
      Original Publication: London : Taylor & Francis, c1996-
    • Subject Terms:
      Disease Progression* ; Lung Neoplasms* ; Mutation*; Carcinoma, Non-Small-Cell Lung/*genetics ; Proto-Oncogene Proteins p21(ras)/*genetics; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Male ; Middle Aged ; Polymerase Chain Reaction ; Proto-Oncogene Proteins p21(ras)/urine ; Survival Rate
    • Abstract:
      Purpose: Using transrenal DNA to detect KRAS mutations in non-small cell lung cancer (NSCLC), the study addressed the clinical impact for longitudinal monitoring and prognostic value for disease outcome.
      Methods: Digital droplet PCR was used to detect the mutant DNA. A total of 200 NSCLC patients were recruited with varying molecular profiles. To ascertain the specificity of transrenal DNA to accurately profile the disease, primary tissues were compared. Subsequently, serial samplings were performed at different treatment cycles to gauge the predictive value.
      Results: Transrenal DNA was successfully detected in all 200 patients. Overall concordance rate for mutant KRAS DNA within urine specimens and primary tissue biopsies was 95% (k = 0.87; 95% CI: 0.82-0.95). Patients with positive results at baseline had lower median overall survival (OS) than the wildtype group. More importantly, longitudinal monitoring of urine specimens showed an increase in the quantity of transrenal DNA, which were highly associated with disease progression and outcome.
      Conclusions: Our study showed a highly associative link to the patient's tumor KRAS profile. Monitoring its variations aided in stratifying patients with worse outcome. Urinary specimens that can be extracted non-invasively presents new opportunities to track patients with KRAS mutation undergoing therapy.
    • Contributed Indexing:
      Keywords: KRAS mutation; NSCLC; cell free DNA; circulating tumor DNA; liquid biopsy; transrenal DNA
    • Accession Number:
      0 (KRAS protein, human)
      EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
    • Publication Date:
      Date Created: 20161222 Date Completed: 20180618 Latest Revision: 20180618
    • Publication Date:
      20240829
    • Accession Number:
      10.1080/1354750X.2016.1269202
    • Accession Number:
      27998182